Detailed Narrative
Revised Outlook and Drivers
UnitedHealth Group revised its FY25 adjusted EPS outlook to $26.00-$26.50, citing two primary factors impacting its Medicare businesses: increased care activity and unanticipated member profiles. The company noted that Q1 FY25 care activity in UnitedHealthcare's Medicare Advantage (MA) business increased at twice the rate observed in 2024, particularly in physician and outpatient services. Separately, Optum Health experienced revenue impacts from new Medicare patients who were less engaged by prior plans and challenges in transitioning to the new CMS risk model (V28).
Medicare Advantage Care Activity Details
The surge in care activity was specific to the MA business, not seen in commercial or Medicaid. It was broad-based across senior individual and group populations. Notably, group MA, with 98% member retention, showed significant increases in elective care, potentially influenced by higher member premiums due to Medicare funding cuts. An earlier and higher volume of wellness visits also drove specialty and outpatient utilization, with follow-on care exceeding expectations. This trend is assumed to persist through 2025 and into 2026 for planning purposes.
Optum Health Member Profile and CMS Risk Model Transition
Optum Health's performance was impacted by the profile of new value-based patients, many of whom were new to Medicare or Optum Health and came from plans that exited markets. These patients had lower engagement with prior plans, leading to lower-than-expected revenues. The transition to the new CMS risk model (V28), a multi-year phase-in, proved more operationally complex than anticipated, especially concerning the higher acuity of Optum Health's patient population. Management acknowledged the need for better execution and is implementing actions like enhancing PCP access, expanding home-based visits, and accelerating EMR unification.
Value-Based Care Strategy Reaffirmation
Despite the current challenges, UnitedHealth Group strongly reaffirmed its confidence in the value-based care model. Management emphasized that the issues are largely 'second-order derivative effects' of significant industry-wide pricing adjustments (e.g., 9% price cut across MA), rather than a fundamental flaw in the value-based care approach. They highlighted that value-based care leads to better patient outcomes, reduced emergency/hospital visits, and lower overall costs, as evidenced by the outperformance of earlier patient cohorts.
PBM Reforms and Policy Landscape
Optum Rx is leading with transparency initiatives, including 100% commercial rebate pass-through, removing prior authorizations on 80 drugs (over 10% of total), and implementing cost-based reimbursement for pharmacies. The company expressed significant concern over new Arkansas legislation regarding PBM and pharmacy ownership, fearing it could cut off patient access to critical medications. Management also welcomed the President's executive order on pharmacy, hoping for a more holistic review of the entire pharmacy value chain rather than solely focusing on PBMs.
Medicaid Rates and Funding
The company noted encouraging progress in Medicaid rates in H2 2024 and Q1 2025, with the gap between population acuity and rate funding narrowing. While acknowledging that funding remains insufficient to meet all patient health needs, UnitedHealth Group remains optimistic about collaborative relationships with states and expects the gap to continue narrowing throughout the year, particularly with the 7/1 rate cycle.
Pharmaceutical Tariff Impact
Regarding potential pharmaceutical tariffs, UnitedHealth Group believes it is well-positioned due to existing price protection mechanisms in contracts and various legislative protections that limit manufacturers' ability to pass on price increases. While acknowledging the dynamic nature of the situation, the company does not anticipate a significant exposure, particularly for the current year, and will thoughtfully consider future bids.